Index
1 Market Overview of Chemotheraphy-induced Nausea and Vomitting Treatment
1.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Overview
1.1.1 Chemotheraphy-induced Nausea and Vomitting Treatment Product Scope
1.1.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Status and Outlook
1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2029)
1.4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Region (2018-2023)
1.5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
1.6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
1.6.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
1.6.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size (2018-2029)
2 Chemotheraphy-induced Nausea and Vomitting Treatment Market by Type
2.1 Introduction
2.1.1 5-HT3 Inhibitors
2.1.2 NK1 Inhibitors
2.1.3 Others
2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Type (2018-2029)
3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Overview by Application
3.1 Introduction
3.1.1 Acute Nausea and Vomitting Treatment
3.1.2 Delayed Nausea and Vomitting Treatment
3.1.3 Anticipatory Nausea and Vomitting Treatment
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Breakdown by Application (2018-2029)
4 Chemotheraphy-induced Nausea and Vomitting Treatment Competition Analysis by Players
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2022)
4.3 Date of Key Players Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
4.4 Global Top Players Chemotheraphy-induced Nausea and Vomitting Treatment Headquarters and Area Served
4.5 Key Players Chemotheraphy-induced Nausea and Vomitting Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.1.4 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Helsinn
5.2.1 Helsinn Profile
5.2.2 Helsinn Main Business
5.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.2.4 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Helsinn Recent Developments
5.3 Heron Therapeutics
5.3.1 Heron Therapeutics Profile
5.3.2 Heron Therapeutics Main Business
5.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.3.4 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Merck & Co Recent Developments
5.4 Merck & Co
5.4.1 Merck & Co Profile
5.4.2 Merck & Co Main Business
5.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.4.4 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Merck & Co Recent Developments
5.5 Tesaro
5.5.1 Tesaro Profile
5.5.2 Tesaro Main Business
5.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.5.4 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Tesaro Recent Developments
5.6 Acacia Pharma
5.6.1 Acacia Pharma Profile
5.6.2 Acacia Pharma Main Business
5.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.6.4 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Acacia Pharma Recent Developments
5.7 Aphios
5.7.1 Aphios Profile
5.7.2 Aphios Main Business
5.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.7.4 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Aphios Recent Developments
5.8 Barr Laboratories
5.8.1 Barr Laboratories Profile
5.8.2 Barr Laboratories Main Business
5.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.8.4 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Barr Laboratories Recent Developments
5.9 Baxter Healthcare
5.9.1 Baxter Healthcare Profile
5.9.2 Baxter Healthcare Main Business
5.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.9.4 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Baxter Healthcare Recent Developments
5.10 Eisai
5.10.1 Eisai Profile
5.10.2 Eisai Main Business
5.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.10.4 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Eisai Recent Developments
5.11 Especificos Stendhal
5.11.1 Especificos Stendhal Profile
5.11.2 Especificos Stendhal Main Business
5.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.11.4 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.11.5 Especificos Stendhal Recent Developments
5.12 F.Hoffmann La Roche
5.12.1 F.Hoffmann La Roche Profile
5.12.2 F.Hoffmann La Roche Main Business
5.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.12.4 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.12.5 F.Hoffmann La Roche Recent Developments
5.13 Mundipharma
5.13.1 Mundipharma Profile
5.13.2 Mundipharma Main Business
5.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.13.4 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.13.5 Mundipharma Recent Developments
5.14 Mylan Pharmaceuticals
5.14.1 Mylan Pharmaceuticals Profile
5.14.2 Mylan Pharmaceuticals Main Business
5.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.14.4 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.14.5 Mylan Pharmaceuticals Recent Developments
5.15 OPKO Health
5.15.1 OPKO Health Profile
5.15.2 OPKO Health Main Business
5.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.15.4 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.15.5 OPKO Health Recent Developments
5.16 Orchid Healthcare
5.16.1 Orchid Healthcare Profile
5.16.2 Orchid Healthcare Main Business
5.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Products, Services and Solutions
5.16.4 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Revenue (US$ Million) & (2018-2023)
5.16.5 Orchid Healthcare Recent Developments
6 North America
6.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
11.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
11.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
11.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
11.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List